Treatment of Lassa virus infection in outbred guinea pigs with first-in-class human monoclonal antibodies.

Abstract

Lassa fever is a significant health threat to West African human populations with hundreds of thousands of annual cases. There are no approved medical countermeasures currently available. Compassionate use of the antiviral drug ribavirin or transfusion of convalescent serum has resulted in mixed success depending on when administered or the donor source, respectively. We previously identified several recombinant human monoclonal antibodies targeting the glycoprotein of Lassa virus with strong neutralization profiles in vitro. Here, we demonstrate remarkable therapeutic efficacy using first-in-class human antibodies in a guinea pig model of Lassa infection thereby presenting a promising treatment alternative.

DOI: 10.1016/j.antiviral.2016.08.012

2 Figures and Tables

Cite this paper

@article{Cross2016TreatmentOL, title={Treatment of Lassa virus infection in outbred guinea pigs with first-in-class human monoclonal antibodies.}, author={Robert W. Cross and Chad E Mire and Luis M Branco and Thomas W Geisbert and Megan M Rowland and Megan L Heinrich and Augustine Goba and Mambu Momoh and Donald S. Grant and Mohamed Fullah and Sheik Humarr Khan and James E Robinson and Thomas W. Geisbert and Robert F Garry}, journal={Antiviral research}, year={2016}, volume={133}, pages={218-222} }